Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Donald Lannin, MD

Professor Emeritus of Surgery (Oncology)

Contact Information

Donald Lannin, MD

Mailing Address

  • Surgical Oncology

    PO Box 208062

    New Haven, CT 06520-8062

    United States

Download CV
Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Lannin’s research interests include surgery for both benign and malignant diseases of the breast including breast cancer; high-risk screening; breast biopsy; sentinel lymph node biopsy; ductal lavage; and ductoscopy. He is a member of the Yale Cancer Center Cancer Prevention and Control (CPC) Research group.

Coauthors

Research Interests

Breast Diseases; Breast Neoplasms; Surgical Oncology

Selected Publications

  • AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast CancersLerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers Clinical Breast Cancer 2022 PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.
  • Breast Cancer Screening: Is There Room for De-escalation?Kim L, Lannin D. Breast Cancer Screening: Is There Room for De-escalation? Current Breast Cancer Reports 2022, 1-9. PMCID: PMC9640864, DOI: 10.1007/s12609-022-00465-z.
  • Breast Cancer Screening: Is There Room for De-escalation?Kim L, Lannin D. Breast Cancer Screening: Is There Room for De-escalation? Current Breast Cancer Reports 2022, 14: 153-161. PMID: 36404936, PMCID: PMC9640864, DOI: 10.1007/s12609-022-00465-z.
  • ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction RatesLe Blanc J, Golshan M, Lannin D, Greenup R, Berger E, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastrioanni M, Park T. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates Annals Of Surgical Oncology 2022, 29: 2191-2192. DOI: 10.1245/s10434-021-10944-9.
  • The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ PatientsTrant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.
  • ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation SurgeryChagpar A, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin D. ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery Annals Of Surgical Oncology 2021, 28: 632-632. DOI: 10.1245/s10434-021-10584-z.
  • How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
  • Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
  • Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.
  • The effect of black cohosh on Ki67 levels in DCIS patients.Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.
  • Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast CancerChagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.
  • Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB)Chiu AS, Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR. Regional variation in breast cancer surgery: Results from the National Cancer Database (NCDB) The American Journal Of Surgery 2017, 214: 907-913. PMID: 28736057, DOI: 10.1016/j.amjsurg.2017.07.008.
  • Are Small Breast Cancers Good because They Are Small or Small because They Are Good?Lannin DR, Wang S. Are Small Breast Cancers Good because They Are Small or Small because They Are Good? New England Journal Of Medicine 2017, 376: 2286-91. PMID: 28591529, DOI: 10.1056/nejmsr1613680.
  • Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
  • Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
  • Duration of neoadjuvant endocrine therapy and breast cancer outcomes.Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.
  • Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution ExperienceBerrocal J, Saperstein L, Grube B, Horowitz NR, Chagpar AB, Killelea BK, Lannin DR. Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience Surgery Research And Practice 2017, 2017: 5924802. PMID: 28492062, PMCID: PMC5406738, DOI: 10.1155/2017/5924802.
  • Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011Killelea BK, Chagpar AB, Horowitz NR, Lannin DR. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011 The American Journal Of Surgery 2016, 213: 426-432. PMID: 27769548, DOI: 10.1016/j.amjsurg.2016.05.018.
  • Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trialChagpar A, Longley P, Horowitz N, Killelea B, Tsangaris T, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin D, Pusztai L, Loftus M, Davidoff A, Gross C. Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial Cancer Research 2016, 76: p3-13-01-p3-13-01. DOI: 10.1158/1538-7445.sabcs15-p3-13-01.
  • Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancerKillelea B, Chagpar A, Horowitz N, Pusztai L, Wang S, Mougalian S, Lannin D. Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer Cancer Research 2016, 76: p1-09-01-p1-09-01. DOI: 10.1158/1538-7445.sabcs15-p1-09-01.
  • Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011Killelea B, Chagpar A, Horowitz N, Lannin D. Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011 Journal Of The American College Of Surgeons 2015, 221: e4. DOI: 10.1016/j.jamcollsurg.2015.08.310.
  • Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).Gnanajothy R, Chung G, DiGiovanna M, Abu-Khalaf M, Lannin D, Harris L. Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH). Journal Of Clinical Oncology 2015, 33: 144-144. DOI: 10.1200/jco.2015.33.28_suppl.144.
  • Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsiesShi W, Chagpar A, Jiang T, Lannin D, Killelea B, Horowitz N, Lim R, Platt J, Ng C, Wali V, Weigelt B, Reis-Filho J, Hatzis C, Pusztai L. Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies 2015, pd3-4-pd3-4. DOI: 10.1158/1538-7445.sabcs14-pd3-4.
  • Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer DatabaseChagpar A, Mougalian S, Lannin D, Abu-Khalaf M, Killelea B, Sanft T, Pusztai L. Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database 2015, p3-07-11-p3-07-11. DOI: 10.1158/1538-7445.sabcs14-p3-07-11.
  • Abstract P3-11-02: Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011Yang V, Han G, Mougalian S, Killelea B, Horowitz N, Chagpar A, Hayse B, Pusztai L, Lannin D. Abstract P3-11-02: Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011 2015, p3-11-02-p3-11-02. DOI: 10.1158/1538-7445.sabcs14-p3-11-02.
  • Abstract P5-03-01: Breast cancer biology varies dramatically by method of detection and may account for overdiagnosisHayse B, Kanumuri P, Killelea B, Horowitz N, Chagpar A, Lannin D. Abstract P5-03-01: Breast cancer biology varies dramatically by method of detection and may account for overdiagnosis 2015, p5-03-01-p5-03-01. DOI: 10.1158/1538-7445.sabcs14-p5-03-01.
  • Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.
  • Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.Brown J, Bai Y, Bossuyt V, Nixon C, Lannin D, Rimm D. Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1027-1027. DOI: 10.1200/jco.2014.32.15_suppl.1027.
  • Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United StatesMougalian S, Abu-Khalaf M, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States Cancer Research 2013, 73: p3-14-02-p3-14-02. DOI: 10.1158/0008-5472.sabcs13-p3-14-02.
  • Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United StatesHofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States Cancer Research 2013, 73: p5-13-05-p5-13-05. DOI: 10.1158/0008-5472.sabcs13-p5-13-05.
  • Does removal of DCIS decrease the incidence of invasive breast cancer?Killelea B, Christy C, Horowitz N, Tsangaris T, Dixon M, Chagpar A, Grube B, Lannin D. Does removal of DCIS decrease the incidence of invasive breast cancer? Journal Of Clinical Oncology 2013, 31: 2-2. DOI: 10.1200/jco.2013.31.26_suppl.2.
  • Triple-negative breast cancer: molecular characterization and targeted therapiesNicholson A, Bishop J, Lannin D, Killelea B, Guo X, Cha C, Dixon J. Triple-negative breast cancer: molecular characterization and targeted therapies Breast Cancer Management 2013, 2: 417-430. DOI: 10.2217/bmt.13.40.
  • A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.
  • Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study.Sinclair N, Sakr B, Abu-Khalaf M, Somlo G, Black R, Chung G, Rizack T, Strenger R, Fenton M, DiGiovanna M, Constantinou M, Lannin D, Legare R, Chagpar A, Sambandam S, Bossuyt V, Rosati K, Harris L, Sikov W. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. Journal Of Clinical Oncology 2013, 31: 619-619. DOI: 10.1200/jco.2013.31.15_suppl.619.
  • Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.
  • Abstract 1365: Sun protection practices among melanoma survivors.Puthumana J, Ferrucci L, Mayne S, Lannin D, Chagpar A. Abstract 1365: Sun protection practices among melanoma survivors. Cancer Research 2013, 73: 1365-1365. DOI: 10.1158/1538-7445.am2013-1365.
  • The Prognostic Implications of Histologic Subtype of Ductal Carcinoma in SituSue G, Lannin D, Killelea B, Horowitz N, Tsangaris T, Chagpar A. The Prognostic Implications of Histologic Subtype of Ductal Carcinoma in Situ Journal Of Surgical Research 2013, 179: 193. DOI: 10.1016/j.jss.2012.10.224.
  • Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).Colavito S, Stepansky A, Madan A, Harris L, Hicks J, Bossuyt V, Rimm D, Lannin D, Stern D. Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Cancer Research 2012, 72: p3-14-01-p3-14-01. DOI: 10.1158/0008-5472.sabcs12-p3-14-01.
  • Abstract P3-14-05: Recurrence in Patients Diagnosed with Ductal Carcinoma in Situ: Predictors and Prognostic SignificanceSue G, Killelea B, Horowitz N, Lannin D, Chagpar A. Abstract P3-14-05: Recurrence in Patients Diagnosed with Ductal Carcinoma in Situ: Predictors and Prognostic Significance Cancer Research 2012, 72: p3-14-05-p3-14-05. DOI: 10.1158/0008-5472.sabcs12-p3-14-05.
  • Abstract P3-14-06: The Utility of Margin Index to Predict Residual DCIS Following Breast Conserving SurgeryAneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Abstract P3-14-06: The Utility of Margin Index to Predict Residual DCIS Following Breast Conserving Surgery Cancer Research 2012, 72: p3-14-06-p3-14-06. DOI: 10.1158/0008-5472.sabcs12-p3-14-06.
  • Abstract P4-01-02: Association of DCE-MRI texture features with molecular phenotypes and neoadjuvant therapy response in breast cancerBanerjee N, Maity S, Varadan V, Janevski A, Kamalakaran S, Sikov W, Abu-Khalaf M, Bossuyt V, Lannin D, Harris L, Cornfeld D, Dimitrova N. Abstract P4-01-02: Association of DCE-MRI texture features with molecular phenotypes and neoadjuvant therapy response in breast cancer Cancer Research 2012, 72: p4-01-02-p4-01-02. DOI: 10.1158/0008-5472.sabcs12-p4-01-02.
  • Predictors of residual disease after breast-conserving surgery.Aneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of residual disease after breast-conserving surgery. Journal Of Clinical Oncology 2012, 30: 168-168. DOI: 10.1200/jco.2012.30.27_suppl.168.
  • Predictors of microinvasion and its prognostic role in ductal carcinoma in situ.Sue G, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Journal Of Clinical Oncology 2012, 30: 188-188. DOI: 10.1200/jco.2012.30.27_suppl.188.
  • Accuracy of breast MRI in predicting pathologic tumor size.Caprio K, Caprio K, Chagpar A, Hooley R, Tavassoli F, Honarpishe H, Honarpishe H, Lannin D, Killelea B, Killelea B, Horowitz N, Horowitz N. Accuracy of breast MRI in predicting pathologic tumor size. Journal Of Clinical Oncology 2012, 30: 1109-1109. DOI: 10.1200/jco.2012.30.15_suppl.1109.
  • Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.
  • Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.
  • Abstract 691: Estrogen receptor mRNA level in breast cancer predicts response to tamoxifenBordeaux J, Cheng H, Welsh A, Haffty B, Lannin D, Wu X, Su N, Ma X, Luo Y, Rimm D. Abstract 691: Estrogen receptor mRNA level in breast cancer predicts response to tamoxifen Cancer Research 2012, 72: 691-691. DOI: 10.1158/1538-7445.am2012-691.
  • Surgical Intervention Following Neoadjuvant Chemotherapy in Breast CancerSowden M, Grube B, Killilea B, Lannin D. Surgical Intervention Following Neoadjuvant Chemotherapy in Breast Cancer 2012 DOI: 10.5772/24519.
  • P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.
  • P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11?Lannin D, Killelea B, Grube B, Horowitz N, Chagpar A. P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11? Cancer Research 2011, 71: p3-07-26-p3-07-26. DOI: 10.1158/0008-5472.sabcs11-p3-07-26.
  • Breast Conservation Therapy for Ductal Carcinoma In Situ (DCIS): Is there a difference in Clinical-Pathologic Features and Long Term Outcomes in Occult, Mammographically-Detected Disease Compared with DCIS Presenting with Physical Findings?Bai H, Lannin D, Higgins S, Motwani S, Hafty B, Goyal S, Wilson L, Evans S, Moran M. Breast Conservation Therapy for Ductal Carcinoma In Situ (DCIS): Is there a difference in Clinical-Pathologic Features and Long Term Outcomes in Occult, Mammographically-Detected Disease Compared with DCIS Presenting with Physical Findings? International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s245. DOI: 10.1016/j.ijrobp.2011.06.1716.
  • Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens.Kamalakaran S, Lezon-Geyda K, Varadan V, Banerjee N, Lannin D, Rizack T, Sikov W, Abu-Khalaf M, Janevski A, Harris L. Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens. Journal Of Clinical Oncology 2011, 29: 46-46. DOI: 10.1200/jco.2011.29.27_suppl.46.
  • Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.Killelea B, Grube B, Philpotts L, Sowden M, Horowitz N, Lannin D. Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. Journal Of Clinical Oncology 2011, 29: 67-67. DOI: 10.1200/jco.2011.29.27_suppl.67.
  • Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy.Lannin D, Grube B, Killelea B, Horowitz N, Harris L. Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy. Journal Of Clinical Oncology 2011, 29: 100-100. DOI: 10.1200/jco.2011.29.27_suppl.100.
  • Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study.Sinclair N, Abu-Khalaf M, Sakr B, Rizack T, Lannin D, Gass J, Strenger R, Bossuyt V, Fenton M, Harris L, Sikov W. Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study. Journal Of Clinical Oncology 2011, 29: e11573-e11573. DOI: 10.1200/jco.2011.29.15_suppl.e11573.
  • P222 Contralateral prophylactic nipple sparing mastectomy for unilateral breast cancerGrube B, Tran E, Killelea B, Tavassoli F, Lannin D, Keleifa S. P222 Contralateral prophylactic nipple sparing mastectomy for unilateral breast cancer The Breast 2011, 20: s52-s53. DOI: 10.1016/s0960-9776(11)70169-2.
  • Molecular Classification of Normal and Cancer Mammospheres.Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.
  • Reply to “Preoperative Chemotherapy and Potential Impact on Re-Excision for Early Breast Cancer”Christy C, Grube B, Lannin D. Reply to “Preoperative Chemotherapy and Potential Impact on Re-Excision for Early Breast Cancer” Annals Of Surgical Oncology 2009, 16: 2958-2959. DOI: 10.1245/s10434-009-0588-0.
  • Association between HER2/neu overexpression and calcifications in breast cancerChristy C, Rishi M, Schwartz J, Grube B, Bossuyt V, Philpotts L, DiGiovanna M, Tavassoli F, Lannin D. Association between HER2/neu overexpression and calcifications in breast cancer Journal Of Clinical Oncology 2009, 27: 579-579. DOI: 10.1200/jco.2009.27.15_suppl.579.
  • Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biologySchwartz J, Christy C, Grube B, Rishi M, Tavassoli F, Bossuyt V, Harris L, DiGiovanna M, Lannin D. Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology Journal Of Clinical Oncology 2009, 27: 633-633. DOI: 10.1200/jco.2009.27.15_suppl.633.
  • COX-2 expression in post-mastectomy chest wall relapseKim J, Bossuyt V, Lannin D, Haffty B. COX-2 expression in post-mastectomy chest wall relapse Journal Of Clinical Oncology 2005, 23: 579-579. DOI: 10.1200/jco.2005.23.16_suppl.579.
  • Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?Haffty B, Lannin D. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? European Journal Of Cancer 2004, 40: 1105-1108. PMID: 15110872, DOI: 10.1016/j.ejca.2004.01.032.
  • Preoperative chemotherapy and sentinel lymphadenectomy for breast cancerTafra L, Verbanac K, Lannin D. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer The American Journal Of Surgery 2001, 182: 312-315. PMID: 11720661, DOI: 10.1016/s0002-9610(01)00718-8.
  • Comparison of Intradermal and Subcutaneous Injections in Lymphatic MappingKersey T, Van Eyk J, Lannin D, Chua A, Tafra L. Comparison of Intradermal and Subcutaneous Injections in Lymphatic Mapping Journal Of Surgical Research 2001, 96: 255-259. PMID: 11266281, DOI: 10.1006/jsre.2000.6075.
  • Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue DyeTafra L, Lannin D, Swanson M, Van Eyk J, Verbanac K, Chua A, Ng P, Edwards M, Halliday B, Henry C, Sommers L, Carman C, Molin M, Yurko J, Perry R, Williams A. Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye Annals Of Surgery 2001, 233: 51-59. PMID: 11141225, PMCID: PMC1421166, DOI: 10.1097/00000658-200101000-00009.
  • Circadian coordination of cancer growth and metastatic spreadHrushesky W, Lester B, Lannin D. Circadian coordination of cancer growth and metastatic spread International Journal Of Cancer 1999, 83: 365-373. PMID: 10495429, DOI: 10.1002/(sici)1097-0215(19991029)83:3<365::aid-ijc12>3.0.co;2-4.
  • Filtered Versus Unfiltered Technetium Sulfur Colloid in Lymphatic Mapping: A Significant Variable in a Pig ModelTafra L, Chua A, Ng P, Aycock D, Swanson M, Lannin D. Filtered Versus Unfiltered Technetium Sulfur Colloid in Lymphatic Mapping: A Significant Variable in a Pig Model Annals Of Surgical Oncology 1999, 6: 83-87. PMID: 10030419, DOI: 10.1007/s10434-999-0083-7.
  • Evidence for an Ontogenetic Basis for Circadian Coordination of Cancer Cell ProliferationHrushesky W, Lannin D, Haus E. Evidence for an Ontogenetic Basis for Circadian Coordination of Cancer Cell Proliferation Journal Of The National Cancer Institute 1998, 90: 1480-1484. PMID: 9776414, DOI: 10.1093/jnci/90.19.1480.
  • Influence of Socioeconomic and Cultural Factors on Racial Differences in Late-Stage Presentation of Breast CancerLannin D, Mathews H, Mitchell J, Swanson M, Swanson F, Edwards M. Influence of Socioeconomic and Cultural Factors on Racial Differences in Late-Stage Presentation of Breast Cancer JAMA 1998, 279: 1801-1807. PMID: 9628711, DOI: 10.1001/jama.279.22.1801.
  • Fine‐needle aspiration cytology of a subareolar abscess of the male breastSilverman J, Raso D, Elsheikh T, Lannin D. Fine‐needle aspiration cytology of a subareolar abscess of the male breast Diagnostic Cytopathology 1998, 18: 441-444. PMID: 9626518, DOI: 10.1002/(sici)1097-0339(199806)18:6<441::aid-dc11>3.0.co;2-h.
  • Racial Differences in Breast Cancer in a Rural Population: Comparison of Cytologic Nuclear Grade, Other Prognostic Factors, and Outcomes for Tumors Diagnosed by Fine‐Needle Aspiration BiopsyThomas P, Raab S, Lannin D, Slagel D, Silverman J. Racial Differences in Breast Cancer in a Rural Population: Comparison of Cytologic Nuclear Grade, Other Prognostic Factors, and Outcomes for Tumors Diagnosed by Fine‐Needle Aspiration Biopsy The Breast Journal 1998, 4: 104-111. DOI: 10.1046/j.1524-4741.1998.420104.x.
  • Breast Cancer in African‐American FamiliesROYAK‐SCHALER R, DEVELLIS B, SORENSON J, WILSON K, LANNIN D, EMERSON J. Breast Cancer in African‐American Families Annals Of The New York Academy Of Sciences 1995, 768: 281-285. PMID: 8526367, DOI: 10.1111/j.1749-6632.1995.tb12141.x.
  • Difficulties in Diagnosis of Carcinoma of the Breast in Patients Less Than Fifty Years of AgeLannin D, Harris R, Swanson F, Edwards M, Swanson M, Pories W. Difficulties in Diagnosis of Carcinoma of the Breast in Patients Less Than Fifty Years of Age Obstetrical & Gynecological Survey 1994, 49: 255. DOI: 10.1097/00006254-199404000-00017.
  • Coming to terms with advanced breast cancer: Black women's narratives from Eastern North CarolinaMathews H, Lannin D, Mitchell J. Coming to terms with advanced breast cancer: Black women's narratives from Eastern North Carolina Social Science & Medicine 1994, 38: 789-800. PMID: 8184330, DOI: 10.1016/0277-9536(94)90151-1.
  • Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age.Lannin D, Harris R, Swanson F, Edwards M, Swanson M, Pories W. Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Journal Of The American College Of Surgeons 1993, 177: 457-62. PMID: 8211596.
  • Increasing mammography utilization: a controlled study.Fletcher S, Harris R, Gonzalez J, Degnan D, Lannin D, Strecher V, Pilgrim C, Quade D, Earp J, Clark R. Increasing mammography utilization: a controlled study. Journal Of The National Cancer Institute 1993, 85: 112-20. PMID: 8418300, DOI: 10.1093/jnci/85.2.112.
  • Mammography and age: Are we targeting the wrong women? A community survey of women and physiciansHarris R, Fletcher S, Gonzalez J, Lannin D, Degnan D, Earp J, Clark R. Mammography and age: Are we targeting the wrong women? A community survey of women and physicians Cancer 1991, 67: 2010-2014. PMID: 2004318, DOI: 10.1002/1097-0142(19910401)67:7<2010::aid-cncr2820670730>3.0.co;2-8.
  • Fine‐needle aspiration cytology of breast masses in pregnant and lactating womenFinley J, Silverman J, Lannin D. Fine‐needle aspiration cytology of breast masses in pregnant and lactating women Diagnostic Cytopathology 1989, 5: 255-259. PMID: 2791833, DOI: 10.1002/dc.2840050305.
  • The triage role of fine needle aspiration biopsy of palpable breast masses. Diagnostic accuracy and cost-effectiveness.Silverman J, Lannin D, O'Brien K, Norris H. The triage role of fine needle aspiration biopsy of palpable breast masses. Diagnostic accuracy and cost-effectiveness. Acta Cytologica 1987, 31: 731-6. PMID: 3425133.
  • Cost-Effectiveness of Fine Needle Biopsy of the BreastLANNIN D, SILVERMAN J, WALKER C, PORIES W. Cost-Effectiveness of Fine Needle Biopsy of the Breast Annals Of Surgery 1986, 203: 474-480. PMID: 3085603, PMCID: PMC1251147, DOI: 10.1097/00000658-198605000-00005.
  • Fine needle aspiration cytology of subareolar abscess of the breast. Spectrum of cytomorphologic findings and potential diagnostic pitfalls.Silverman J, Lannin D, Unverferth M, Norris H. Fine needle aspiration cytology of subareolar abscess of the breast. Spectrum of cytomorphologic findings and potential diagnostic pitfalls. Acta Cytologica 1986, 30: 413-9. PMID: 3461650.
Edit Profile